Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.52 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.51 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.51 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.51 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.51 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | IDE | P14735 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083888 | 0.88 | TRPV1 (0.79) | TRPV1KMT2AMEN1TSHRKCNQ3 | |
| SCHEMBL14083938 | 0.88 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL14083913 | 0.85 | GRM4 (0.60) | TRPV1KMT2AMEN1HPGD | |
| SCHEMBL14083939 | 0.85 | GRM4 (0.66) | TRPV1KMT2AMEN1 | |
| SCHEMBL14084016 | 0.84 | P2RX1 (0.51) | TRPV1TSHRHPGD | |
| SCHEMBL14083942 | 0.84 | TRPV1 (0.57) | TRPV1KDM4EMAPK1 | |
| SCHEMBL14083040 | 0.83 | MEN1 (0.53) | TRPV1KMT2AMEN1HPGDTDP1 | |
| SCHEMBL14083367 | 0.83 | TRPV1 (0.64) | TRPV1KMT2AMEN1EPAS1RXFP1 | |
| SCHEMBL14083925 | 0.83 | TRPV1 (0.47) | TRPV1KMT2AMEN1 | |
| SCHEMBL14083956 | 0.83 | TRPV1 (0.55) | TRPV1KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885KMT2A 4272/4885MEN1 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.